{
  "abstract": "We thank Gao and Liu for their thoughtful comments on our study and for highlighting two important issues regarding the implementation of non-invasive test-based hepatocellular carcinoma (HCC) surveillance in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).1 2 Our study was a large multicentre longitudinal cohort of 12 950 patients with MASLD, among whom 109 developed incident HCC over a median follow-up of 47.7 months. The study aimed to define practical Fibrosis-4 index (FIB-4) and liver stiffness measurement (LSM) by vibration-controlled transient elastography thresholds associated with annual HCC incidences exceeding currently accepted surveillance benchmarks.3",
  "authors": [
    {
      "affiliations": [
        "Department of Medicine and Therapeutics, The Chinese University of Hong Kong Faculty of Medicine, Hong Kong, Hong Kong, Hong Kong",
        "Medical Data Analytics Centre, The Chinese University of Hong Kong Faculty of Medicine, Hong Kong, Hong Kong",
        "Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong Faculty of Medicine, Hong Kong, Hong Kong"
      ],
      "name": "Jimmy Che To Lai"
    },
    {
      "affiliations": [
        "Department of Medicine and Therapeutics, The Chinese University of Hong Kong Faculty of Medicine, Hong Kong, Hong Kong, Hong Kong",
        "Medical Data Analytics Centre, The Chinese University of Hong Kong Faculty of Medicine, Hong Kong, Hong Kong",
        "Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong Faculty of Medicine, Hong Kong, Hong Kong"
      ],
      "name": "Terry Cheuk-Fung Yip"
    }
  ],
  "title": "Reply to the letter to the editor from Gao and Liu regarding ‘Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease’",
  "uid": "ce7278b3-1485-57c9-9a17-63997570c537"
}